Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | HRAS Q61L |
Therapy | PLX7904 |
Indication/Tumor Type | skin squamous cell carcinoma |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
HRAS Q61L | skin squamous cell carcinoma | no benefit | PLX7904 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, PLX7904 did not stimulate growth of Zelboraf (vemurafenib)-induced cutaneous squamous cell carcinoma cells harboring HRAS Q61L in culture or in cell line xenograft models (PMID: 26466569). | 26466569 |
PubMed Id | Reference Title | Details |
---|---|---|
(26466569) | RAF inhibitors that evade paradoxical MAPK pathway activation. | Full reference... |